SAR 408701

Drug Profile

SAR 408701

Alternative Names: SAR408701

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator ImmunoGen
  • Developer Sanofi
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 29 Nov 2016 Adverse events, efficacy and pharmacokinetics data from a phase I trial in Solid tumours presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
  • 07 Oct 2016 SAR 408701 is still in phase I trials for Solid tumours (Late-stage disease, Metastatic disease) in Canada (NCT02187848)
  • 15 Sep 2016 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in South Korea, Spain and France (IV) before September 2016 (NCT02187848)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top